CSF1R and melanoma: In a mouse model of melanoma, the concurrent treatment with CSF-1R inhibitor, PLX3397, and BRAF inhibitor, Vemurafenib, resulted in enhanced anti-tumor responses attributed to a significant reduction of tumor-infiltrating myeloid cells and an increase of tumor-infiltrating lymphocytes (52).